Lululemon (LULU) shares are printing a 2% downtick this morning despite Guggenheim naming the yoga wear maker’s stock as its “Best Idea” with ‘Buy’ rating. The broker cited strong same-store sales growth and continuing momentum.
Shares of Prima Biomed Ltd. (PBMD) are up more than 43% in pre-market morning trading Tuesday after the company announced that it received positive Scientific Advice from the European Medicines Agency [EMA] on the development path for its lead product, IMP321 in metastatic breast cancer.
London-based EMA is the agency responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. After dialogue between Prima and the EMA, the Agency has now confirmed in writing its endorsement of the development program of IMP321 in metastatic breast cancer.
Oramed Pharmaceuticals Inc. (ORMP) stock ran up 8.54% in premarket trade Tuesday, after the company announced the signing of Letter of Intent for an investment and license agreement in China with with Sinopharm Capital and Hefei Life Science & Technology potentially valued at $50 million plus royalty payments.
Oramed said it will receive $500,000 in exchange for exclusively negotiating with Sinopharm/Hefei for 60 days, while the final terms of the agreement are negotiated and finalized.
Shares of SunEdison, Inc. (SUNE) are up 4% this morning on news TerraForm Power (TERP) and SunEdison have signed a definitive agreement to acquire net ownership of 930 megawatt of wind power plants from Invenergy Wind for $2 billion. TerraForm also raised its 2016 dividend target.
Shares of Mazor Robotics Ltd. (MZOR) are up more than 5% to $14 in pre-market trading Tueswday after the company announced today that it received 7 purchase orders for its Renaissance Systems in the second quarter ended June 30, 2015. Six of the systems were delivered to U.S. hospitals and one was delivered to Spain.
Advanced Micro Devices (AMD) shares tumbled 18.22% in active pre-market trade Tuesday following the release of the co.’s 2Q15 guidance. The semiconductor maker is expecting Q2/15 revenue to be down 8% from Q1/15 compared to the prior forecast for a 3% drop.
Advanced Micro Devices said the expected decline in revenue is due to worse-than-anticipated PC demand affecting APU sales into PC OEMs.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!